TY - JOUR
T1 - A gonadotropin releasing hormone analogue prevents cyclical attacks of porphyria
AU - Anderson, K. E.
AU - Spitz, I. M.
AU - Bardin, C. W.
AU - Kappas, A.
PY - 1990
Y1 - 1990
N2 - Acute intermittent porphyria is a genetic disease in which endogenous hormones affect clinical expression. Premenstrual exacerbations can occur, sometimes often, in women with this disease. Gonadotropin releasing hormone analogues can prevent ovulation by reducing secretion of luteinizing hormone and follicle-stimulating hormone. In six patients with well-documented acute intermittent porphyria and frequent cyclical exacerbations, daily administration of an agonistic gonadotropin releasing hormone analogue, ([lmBzl]-D-His6,Pro9-NET)gonadotropin releasing hormone, intranasally or subcutaneously for as long as 26 months reduced or eliminated premenstrual attacks and caused only minor side effects. Adjustments in dosage or route of administration were sometines needed. We conclude that endocrine manipulation by treatment with a gonadotropin releasing hormone agonist will prevent neurovisceral attacks at acute intermittent porphyria due to cyclical changes in endogenous hormones and is a safe alternative to exogenous steroids, which may induce attacks of this disease.
AB - Acute intermittent porphyria is a genetic disease in which endogenous hormones affect clinical expression. Premenstrual exacerbations can occur, sometimes often, in women with this disease. Gonadotropin releasing hormone analogues can prevent ovulation by reducing secretion of luteinizing hormone and follicle-stimulating hormone. In six patients with well-documented acute intermittent porphyria and frequent cyclical exacerbations, daily administration of an agonistic gonadotropin releasing hormone analogue, ([lmBzl]-D-His6,Pro9-NET)gonadotropin releasing hormone, intranasally or subcutaneously for as long as 26 months reduced or eliminated premenstrual attacks and caused only minor side effects. Adjustments in dosage or route of administration were sometines needed. We conclude that endocrine manipulation by treatment with a gonadotropin releasing hormone agonist will prevent neurovisceral attacks at acute intermittent porphyria due to cyclical changes in endogenous hormones and is a safe alternative to exogenous steroids, which may induce attacks of this disease.
UR - http://www.scopus.com/inward/record.url?scp=0025276896&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025276896&partnerID=8YFLogxK
U2 - 10.1001/archinte.150.7.1469
DO - 10.1001/archinte.150.7.1469
M3 - Article
C2 - 2196028
AN - SCOPUS:0025276896
SN - 0003-9926
VL - 150
SP - 1469
EP - 1474
JO - Archives of Internal Medicine
JF - Archives of Internal Medicine
IS - 7
ER -